Zydus Cadila
-
Zydus Cadila vaccine for 12-18 age group soon: Centre informs SC
India | Jun 27, 2021, 07:55 AM ISTZydus Cadila has concluded its clinical trials for the 12 to 18 age group, and the vaccine may be available in near future, subject to the statutory permissions.
-
Zydus Cadila gets nod for clinical trials of antibodies cocktail to treat COVID
Business | Jun 04, 2021, 08:32 AM ISTZydus said that its biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralising monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild COVID-19.
-
Covid-19: Zydus seeks DCGI nod to undertake clinical trials for monoclonal antibodies cocktail
India | May 27, 2021, 01:41 PM ISTZydus said it is the only Indian company to have developed a neutralizing monoclonal antibody based cocktail for the treatment of COVID-19.
-
Zydus Cadila's Virafin gets DGCI approval for treating moderate Covid infection in adults
India | Apr 24, 2021, 12:06 AM ISTDrugs Controller General of India (DGCI) has approved emergency use for Zydus Cadila's Pegylated Interferon alpha-2b, 'Virafin' for treating moderate COVID-19 infection in adults.
-
Zydus Cadila seeks DCGI nod for use of hepatitis drug for COVID-19 treatment
India | Apr 05, 2021, 02:02 PM ISTDrug firm Zydus Cadila on Monday said it has sought approval from the domestic drug regulator Drugs Controller General of India (DCGI) for the additional indication of its hepatitis drug Pegylated Interferon Alpha-2b for treating COVID-19.
-
Zydus Cadila says 'positive results' from phase 2 studies of COVID-19 drug Desidustat in Mexico
World | Jan 25, 2021, 11:31 AM ISTZydus Cadila, which is part of Cadila Healthcare, said: "Patients infected with COVID-19 have been reported to display signs of 'Hypoxia' leading to organ failure and death despite the use of antivirals, anti-inflammatory drugs or ventilators.
-
Zydus Cadila gets USFDA nod for thyroid drug
World | Jan 23, 2021, 12:08 PM ISTDrug firm Zydus Cadila has received final approval from the US health regulator to market Liothyronine Sodium tablets that are used to treat underactive thyroid.
-
Zydus Cadila gets DCGI nod to initiate Phase-3 clinical trials for COVID-19 vaccine
India | Jan 03, 2021, 04:46 PM ISTDrug firm Zydus Cadila on Sunday said it has received DCGI approval to initiate Phase III clinical trials of its COVID-19 vaccine ZyCoV-D.
-
Non-alcoholic fatty liver disease: Zydus Cadila receives DCGI nod for NAFLD drug in India
India | Dec 30, 2020, 11:23 AM ISTDrug firm Zydus Cadila on Wednesday said it has received approval from the Drug Controller General of India (DCGI) for Saroglitazar Mg, used for the treatment of non-alcoholic fatty liver disease (NAFLD), in the country.
-
Zydus Cadila seeks govt nod to start Phase-III clinical trials of COVID-19 vaccine
India | Dec 24, 2020, 10:10 PM ISTThe Phase-II study of the vaccine, ZyCoV-D, had been conducted in over 1,000 healthy adult volunteers as part of the adaptive Phase-I and II dose escalation, multi-centric, randomised and double-blind placebo controlled study.
-
Zydus Cadila gets permission from DCGI for phase-1 clinical trial of novel molecule ZYIL1
India | Dec 07, 2020, 01:00 PM ISTDrug firm Zydus Cadila on Monday said it has received permission from Drugs Controller General of India (DCGI) to initiate phase-1 clinical trial of its novel molecule ZYIL1, indicated for use as an inhibitor for inflammation condition 'NLRP3'.
-
Pfizer's India arm seeks government's nod for emergency use of Covid vaccines
News | Dec 07, 2020, 09:40 AM ISTPfizer India has become the first pharmaceutical firm to seek from the DCGI an emergency use authorisation for its COVID-19 vaccine in the country, after its parent company secured such clearance in the UK and Bahrain.
-
COVID-19 vaccine: Zydus Cadila gets DGCI nod for phase 3 trials of Pegylated Interferon Alpha-2
India | Dec 04, 2020, 12:24 PM ISTIn a regulatory filing, Zydus Cadila said it has received approval from the DCGI to start the phase 3 clinical trials in COVID-19 patients with its biological therapy Pegylated Interferon alpha-2b or PegiHep.
-
PM Modi's presence to motivate company in quest to bridge unmet healthcare needs: Zydus Cadila
India | Nov 28, 2020, 04:00 PM ISTPM Modi visited Zydus Cadila's manufacturing facility near Ahmedabad, as he began his three-city visit to review ongoing coronavirus vaccine development work.
-
Gujarat: PM Modi reviews COVID-19 vaccine development at Zydus Cadila facility
India | Nov 28, 2020, 03:06 PM ISTWearing a PPE kit, Modi reviewed the vaccine development process at the Zydus Cadila research centre in Changodar industrial area, over 20 km from Ahmedabad.
-
PM Modi visits Bharat Biotech facility in Hyderabad to review COVID vaccine development
India | Nov 28, 2020, 03:08 PM ISTThe PM will be flying back to the national capital after a stopover in Pune, where he will visit the Serum Institute of India (SII), which has partnered with pharma giant AstraZeneca and the Oxford University for the vaccine. Earlier in the morning, Modi visited Zydus Cadila''s plant near Ahmedabad.
-
PM Modi's 3-city tour to take stock of COVID-19 vaccine development on Saturday
India | Nov 27, 2020, 11:05 PM ISTPrime Minister Narendra Modi will embark on a three-city visit tomorrow to personally review the coronavirus vaccines development and manufacturing process.
-
Zydus Cadila gets tentative nod from USFDA to market diabetes drug
India | Oct 29, 2020, 12:50 PM ISTZydus Cadila on Thursday said it has received tentative approval from the US health regulator to market Linagliptin tablets, used to treat type 2 diabetes in adults.
-
Zydus Cadila gets USFDA nod for overactive bladder treatment drug
World | Oct 20, 2020, 11:39 AM ISTDrug firm Zydus Cadila on Tuesday said it has received final approval from the US health regulator to market Solifenacin Succinate tablets, used for treatment of overactive bladder.
-
Zydus Cadila gets tentative USFDA nod for generic drug
India | Oct 19, 2020, 12:56 PM ISTDrug firm Zydus Cadila on Monday said it has received tentative approval from the US health regulator to market Tofacitinib extended-release tablets, used to treat ulcerative colitis, in the American market.